Sales of antitumor drugs are 2 times ahead of the overall growth of the global pharmaceutical market
Consulting company "IMS Health" predicts the continuation of the growth rate of the global market of antitumor drugs (by 12-15%) and an increase in their sales to 75-80 billion dollars. USA by 2012 These indicators will almost double the growth of the global pharmaceutical market (increased by 6.4% in 2007). The moderate growth rates of the pharmaceutical market as a whole reflect the difficulties with financing from payers, a gradual decrease in sales of modern blockbuster drugs, the introduction of fewer new blockbusters to the market, in addition, the patent protection period for 4 oncological drugs, whose annual sales exceed $ 1 billion, will expire. In 2008, the volume of sales of antitumor drugs will exceed $ 48 billion, providing about 17% of the increase in sales of the global pharmaceutical market, suggests IMS Health.
According to Titus Plattel, Vice president of IMS Health for oncology, the increase in sales of antitumor drugs will be provided by drugs introduced to the market over the past decade aimed at specific targets, as well as a longer period of treatment of an increasing number of patients.
According to the forecast of IMS Health in 2008, the growth of the market of oncological drugs in the period up to 2012 will be influenced by the following factors:
- limited funds lead to a more careful selection of drugs. Data on survival rates become the main factors determining the decision to issue marketing permits and reimburse the cost of medicines;
- improving screening, diagnosis and access to innovative drugs in developing countries. The largest contribution to market growth will be made by China, Brazil, South Korea, India, Turkey and Russia;
- new drugs and combined treatment regimens. In the period from 2008 to 2012, 25-30 new drugs can be expected to be introduced to the market. Many of them will be aimed at combating the most common tumors – breast cancer and non-small cell lung cancer, and some will be indicated for the treatment of prostate and pancreatic cancer, as well as melanoma;
- reducing the contribution of the main markets to the growth of the market of oncological drugs. In 2007, the share of the USA and 5 major European markets (France, Germany, Italy, Great Britain and Spain) in total sales of anticancer drugs reached 71%. By 2012, this figure may reach about 65%.
Weekly "Pharmacy"Portal "Eternal youth" www.vechnayamolodost.ru